

ANGIOTENSIN RECEPTOR BLOCKER (ARB) COMPARISON CHART

	Losartan [†]	Candesartan	Irbesartan	Olmesartan	Telmisartan	Valsartan
FDA Indications	Hypertension with LVH Nephropathy (type 2 DM)	Hypertension Heart Failure	Hypertension Nephropathy (type 2 DM)	Hypertension	Hypertension CV risk reduction in patients unable to take ACE Inhibitors	Hypertension Heart Failure (Class II to IV) Post-MI with left ventricular dysfunction/failure
Dosage Forms (mg)	25mg 50mg 100mg	4mg 8mg 16mg 32mg	75mg 150mg 300mg	5mg 20mg 40mg	20mg 40mg 80mg	40mg 80mg 160mg 320mg
Initial Dose	HTN: 50mg QD HTN w LVH: 50mg QD Nephropathy: 50mg QD CHF: 12.5mg QD	HTN: 16mg QD CHF: 4mg QD	HTN: 150mg QD	HTN: 20mg QD	HTN: 40mg QD CV Risk Reduction: 80mg QD	HTN: 80-160mg QD CHF: 40mg BID Post-MI: 20mg BID
Maintenance Dose	HTN: 25-100mg QD or divided into BID HTN w LVH: 50-100mg QD Nephropathy: 100mg QD CHF: 150mg QD	HTN: 8-32mg QD or divided into BID CHF: 32mg QD	HTN: 150-300mg QD Nephropathy: 300mg QD	HTN: 20-40mg QD	HTN: 40-80mg QD CV Risk Reduction: 80mg QD	HTN: 80-320mg QD CHF: 40-160mg BID Post-MI: 20-160mg BID
Protein Binding	99.8%	>99%	90-92%	99%	>99.5%	94-97%
Terminal Half-Life	6-9 hours	5-9 hours	11-15 hours	12-15 hours	Approx 24 hours	6-9 hours
Elimination	65% Hepatic (CYP450) 35% Renal	60% Hepatic (CYP450) 40% Renal	80% Hepatic (CYP450) 20% Renal	60% Hepatic (No CYP450) 40% Renal	98% Hepatic (No CYP450) 2% Renal	69% Hepatic (No CYP450) 31% Renal

***Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. When pregnancy is detected, discontinue any ARB as soon as possible.**

† Product in stock for Blessings International.